AL·Async + video
Telehealth · VT
Vermont
Vermont residents can now access GLP-1 medications like semaglutide and tirzepatide through telehealth — from Burlington and Montpelier to Rutland, Brattleboro, and the smallest Green Mountain town. Pallas Health connects you with a board-certified provider licensed in Vermont who can evaluate your eligibility in under 5 minutes and, if appropriate, prescribe medication that ships to any Vermont address in a few business days.
- Licensed by
- Vermont Board of Medical Practice
- Telehealth
- Async + video
- Compounded semaglutide
- Available
- Compounded tirzepatide
- Available
- Medicaid
- Limited coverage
- Shipping
- 2–3 business days
How telehealth prescribing works in Vermont
Vermont permits licensed providers to establish a patient relationship and prescribe non-controlled medications like GLP-1s through telehealth, including synchronous video and store-and-forward (asynchronous) review. Under 26 V.S.A. § 3053a and the Board of Medical Practice telemedicine policy, prescribing via telemedicine is at the provider's professional discretion provided the standard of care is met.
Vermont permits telemedicine broadly under 26 V.S.A. § 3053a and the Vermont Board of Medical Practice Policy on Telemedicine. A health care provider licensed in Vermont may prescribe medications to a patient after performing an appropriate examination in person, through telemedicine, or by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically. Vermont law explicitly recognizes store-and-forward (asynchronous) telehealth, defined as an asynchronous transmission of medical information reviewed at a later date by a provider at a distant site. Prescribing via telemedicine is at the provider's professional discretion, carrying the same professional accountability as in-person prescriptions. Vermont also requires telemedicine providers to post licensure or identifying information about their providers publicly (Vermont Board of Medical Practice Policy on Telemedicine). Pallas publishes its clinical partners (Lion MD and CareValidate), provider leadership, and NPI numbers — with direct links to the federal NPPES NPI Registry — on our clinical disclosures page at pallashealth.co/clinical, where the full prescribing roster's licensure can be verified. Vermont participates in the Interstate Medical Licensure Compact (IMLC), which streamlines licensing for qualifying out-of-state providers. Every Pallas clinician who treats Vermont patients holds an active Vermont license or a qualifying compact license. GLP-1s are not controlled substances, so Vermont's separate Prescription Monitoring System requirements don't add friction here, but our providers still document a complete history, screen for contraindications like personal or family history of medullary thyroid carcinoma, and schedule follow-up visits to monitor response and titrate the dose.
Medicaid & insurance in Vermont
Limited coverage
Vermont Medicaid covers GLP-1 agonists including Wegovy for clinically appropriate needs. However, the Vermont Medicaid State Plan has historically excluded weight-loss-only indications, and coverage may require documented medical necessity beyond obesity alone (e.g. type 2 diabetes, cardiovascular risk). Compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid rules do not affect our pricing.
Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.
Simple cash-pay pricing in Vermont
No insurance, and the same price in every Vermont ZIP code. You see your full price during intake, before you pay anything.
Compounded plans · provider care included
- Compounded semaglutide$139 first month, then $597 every 12 weeks ($199/mo avg)
- Compounded tirzepatide$179 first month, then $897 every 12 weeks ($299/mo avg)
Your plan price covers your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free and discreet, only if prescribed; refunded in full if a clinician decides treatment isn’t right for you. Cancel anytime. Pay-over-time options are available at checkout.
Brand-name · FDA-approved
FDA-approved Wegovy® and Zepbound® for chronic weight management, plus Ozempic® and Mounjaro® for type 2 diabetes, are available cash-pay from $1,069/mo. Your clinician helps determine which option is appropriate for you.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.
Semaglutide vs tirzepatide in Vermont
Both are once-weekly injections available to Vermont patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.
In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide) produced greater average weight loss than Wegovy® (semaglutide) — roughly 20% versus 14% of body weight over 72 weeks — with broadly similar tolerability. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.
Cost and track record differ too: compounded semaglutide plans average $199/mo versus $299/mo for tirzepatide (full terms above), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in Vermont — our full semaglutide vs tirzepatide comparison covers the deeper differences.
Cities served in Vermont
We ship to every ZIP code in Vermont, including:
- Burlington
- Essex
- South Burlington
- Rutland
- Barre
Vermont GLP-1 questions
Yes. Vermont law allows a licensed provider to prescribe medications after an appropriate examination conducted through telemedicine — including asynchronous review of your intake — as long as the standard of care is met. You do not need a prior in-person visit.
Vermont Medicaid covers some GLP-1 agonists for clinically appropriate needs, but coverage for weight-loss-only indications may be limited or excluded under the state plan. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service, so Medicaid rules do not affect our pricing.
Yes. The Vermont Board of Medical Practice Policy on Telemedicine requires telemedicine providers to publicly disclose provider information. Pallas publishes our clinical partners (Lion MD and CareValidate), medical leadership, and NPI numbers — with links to the federal NPPES NPI Registry — on our clinical disclosures page at pallashealth.co/clinical.
Most Vermont patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Burlington, Essex, and South Burlington typically ship fastest; rural Green Mountain ZIP codes may take an extra day.
Yes. Compounded semaglutide prescribed by a Vermont-licensed provider and dispensed by a licensed compounding pharmacy is legal when prepared for an individual patient with a documented clinical need. Pallas works only with U.S. state-licensed 503A and 503B compounding pharmacies.
Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Vermont address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Burlington, Rutland, or a rural Green Mountain ZIP code.
Eligibility is always decided by a Vermont-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.
Brand-name medications — Wegovy® and Ozempic® (semaglutide) and Zepbound® and Mounjaro® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Vermont-licensed provider.
Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Vermont-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.
Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.
The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.
You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Vermont Board of Medical Practice reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Vermont address, usually within 2–3 business days.
Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.
Compounded semaglutide injection through Pallas is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Vermont address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.
Compounded tirzepatide injection through Pallas is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Vermont address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.
Yes. FDA-approved Wegovy® and Zepbound® for chronic weight management — plus Ozempic® and Mounjaro® for type 2 diabetes — are available to Vermont patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Vermont during intake.
That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound® (tirzepatide) produced greater average weight loss than Wegovy® (semaglutide) — about 20% versus 14% of body weight over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Vermont weighs your history, goals, and budget to recommend a starting point.
Start your Vermont intake